Meeting on the Mesa 2021 | Developments in NK cell therapy

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, gives an update of current advancements in allogeneic natural killer (NK) cell therapies. Addition of membrane-bound IL-15 has enabled NK cells to be active for longer, enhancing efficacy when administered in patients. Whilst NK cells are more difficult to cryopreserve compared to chimeric antigen receptor (CAR) T-cells, improvements in cryopreservation techniques have allowed multi-center clinical trials to be successfully conducted. This interview took place at Meeting on the Mesa 2021.